$578.31
0.04% yesterday
Nasdaq, May 20, 10:00 pm CET
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

argenx SE ADR Stock price

$578.31
-17.39 2.92% 1M
-13.51 2.28% 6M
-36.69 5.97% YTD
+216.73 59.94% 1Y
+253.62 78.11% 3Y
+416.78 258.02% 5Y
+555.31 2,414.39% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.21 0.04%
ISIN
US04016X1019
Symbol
ARGX
Sector
Industry

Key metrics

Market capitalization $35.31b
Enterprise Value $31.97b
P/E (TTM) P/E ratio 41.63
EV/FCF (TTM) EV/FCF 1,181.94
EV/Sales (TTM) EV/Sales 14.62
P/S ratio (TTM) P/S ratio 16.15
P/B ratio (TTM) P/B ratio 6.39
Revenue growth (TTM) Revenue growth 78.01%
Revenue (TTM) Revenue $2.19b
EBIT (operating result TTM) EBIT $-75.73m
Free Cash Flow (TTM) Free Cash Flow $27.05m
EPS (TTM) EPS $12.76
P/E forward 48.42
P/S forward 9.75
EV/Sales forward 8.83
Short interest 4.16%
Show more

Is argenx SE ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

argenx SE ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a argenx SE ADR forecast:

31x Buy
91%
3x Hold
9%

Analyst Opinions

34 Analysts have issued a argenx SE ADR forecast:

Buy
91%
Hold
9%

Financial data from argenx SE ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
2,186 2,186
78% 78%
100%
- Direct Costs 236 236
4% 4%
11%
1,950 1,950
95% 95%
89%
- Selling and Administrative Expenses 1,033 1,033
71% 71%
47%
- Research and Development Expense 975 975
29% 29%
45%
-58 -58
84% 84%
-3%
- Depreciation and Amortization 18 18
84% 84%
1%
EBIT (Operating Income) EBIT -76 -76
84% 84%
-3%
Net Profit 831 831
381% 381%
38%

In millions USD.

Don't miss a Thing! We will send you all news about argenx SE ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

argenx SE ADR Stock News

Positive
Seeking Alpha
12 days ago
Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the Medicare redesign. Underlying demand was strong across the globe, and Vyvgart looks well positioned for continued growth, which should be helped by the approval of the PFS and international indicati...
Neutral
Seeking Alpha
12 days ago
argenx SE (NASDAQ:ARGX ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Tazeen Ahmad - Bank of America Alex Thompson - Stifel Vikram P...
Positive
Investors Business Daily
13 days ago
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.
More argenx SE ADR News

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.

Head office Netherlands
CEO Tim Hauwermeiren
Employees 1,599
Founded 2008
Website www.argen-x.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today